NASDAQ •
Healthcare •
Biotechnology •
Quote as of 09/11/2026
Company Profile
IndustryBiotechnology
SectorHealthcare
ExchangeNASDAQ
Market Capitalization2,406.33 mln
Float109 mln
Earnings Date11/16/2026
Piotroski F-Score
3
/ 9
Below average
Beneish M-Score
208
Highly suspicious
1-Year Forecast
36.62
Transformational upside
Relative Strength
14
/ 100
Significantly lagging
Debt / Equity
0.37
Low leverage
Pre-Tax Margin
-544%
Severely loss-making
Business Description
Viridian Therapeutics is a biopharmaceutical company focused on developing medicines for rare and serious conditions, with a particular emphasis on thyroid eye disease and Graves' disease. The company is advancing several drug candidates that work by blocking specific proteins involved in these conditions, including treatments given by injection under the skin as well as through a vein. Founded in 2010 and based in Waltham, Massachusetts, the company rebranded from Miragen Therapeutics in 2021.
